Current and future drug-eluting coronary stent technology

Expert Review of Cardiovascular Therapy

Volumn 9, Issue 4, 2011, Pages 485-503

  Ielasi, Alfonso ^a   Latib, Azeem ^a,b,c   Colombo, Antonio ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

coronary stents; drug eluting stent; polymer; stent thrombosis

Indexed keywords

EVEROLIMUS; PACLITAXEL; PIMECROLIMUS; RAPAMYCIN; ZOTAROLIMUS;

BIOCOMPATIBILITY; BIODEGRADABILITY; CORONARY STENT; DRUG ELUTING STENT; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SAFETY;

CLINICAL TRIALS AS TOPIC; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; FORECASTING; HUMANS;

EID: 79955500374     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.5     Document Type: Review

References (111)

1. Morice MC, Serruys PW, Sousa JE et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346(23), 1773-1780 (2002). (Pubitemid 34586912)
2. Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 349(14), 1315-1323 (2003). (Pubitemid 37186209)
3. Weisz G, Leon MB, Holmes DR Jr et al. Five-year follow-up after sirolimus-eluting stent implanta-tion results of the SIRIUS (Sirolimus-Eluting Stent in de novo Native Coronary Lesions) trial. J. Am. Coll. Cardiol. 53(17), 1488-1497 (2009).
4. Joner M, Finn AV, Farb A et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48(1), 193-202 (2006). (Pubitemid 43929240)
5. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109(6), 701-705 (2004). (Pubitemid 38222887)
6. Joner M, Nakazawa G, Finn AV et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52(5), 333-342 (2008). (Pubitemid 352001347)
7. van der Giessen WJ, Lincoff AM, Schwartz RS et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94(7), 1690-1697 (1996). (Pubitemid 26320276)
8. Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J. Am. Coll. Cardiol. 47(1), 175-181 (2006). (Pubitemid 43005183)
9. Virmani R, Liistro F, Stankovic G et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 106(21), 2649-2651 (2002). (Pubitemid 35364917)
10. Cook S, Ladich E, Nakazawa G et al. Correlation of intravascular ultrasound findings with histopa-thological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis. Circulation 120(5), 391-399 (2009).
11. Nakazawa G, Ladich E, Finn AV, Virmani R. Pathophysiology of vascular healing and stent mediated arterial injury. EuroIntervention 4(Suppl. C), C7-C10 (2008).
12. Serruys PW, Ong AT, Piek JJ et al. A randomized comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent: the SPIRIT first trial. EuroIntervention 1(1), 58-65 (2005).
13. Serruys PW, Ruygrok P, Neuzner J et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2(3), 286-294 (2006).
14. Stone GW, Midei M, Newman W et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 299(16), 1903-1913 (2008). (Pubitemid 351574920)
15. Stone GW, Rizvi A, Newman W et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N. Engl. J. Med. 362(18), 1663-1674 (2010).
16. Kedhi E, Joesoef KS, McFadden E et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 375(9710), 201-209 (2010).
17. Daemen J, Wenaweser P, Tsuchida K et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369(9562), 667-678 (2007). (Pubitemid 46281313)
18. Lin J, Tiong S, Chen C. Surface characterization and platelet adhesion studies on fluorocarbons prepared by plasma-induced graft polymerization J. Biomater. Sci. Polym. 11, 701-714 (2000).
19. Liu TY, Lin WC, Huang LY, Chen SY, Yang MC. Surface characteristics and hemocompatibility of PAN/PVDF blend membranes. Polym. Adv. Technol. 16(5), 413-419 (2005).
20. Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 370(9591), 937-948 (2007). (Pubitemid 47393576)
21. Morice MC, Colombo A, Meier B et al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. JAMA 295(8), 895-904 (2006).
22. Windecker S, Remondino A, Eberli FR et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N. Engl. J. Med. 353(7), 653-662 (2005). (Pubitemid 41175673)
23. Park KW, Yoon JH, Kim JS et al. Efficacy of Xience/promus Versus Cypher in Reducing Late Loss After Stenting (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial. Am. Heart J. 157(5), 811-817.e1 (2009).
24. Rasmussen K, Maeng M, Kaltoft A et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial. Lancet 375(9720), 1090-1099 (2010).
25. Kandzari D. ENDEAVOR III: 5 year final outcomes. Presented at: The American College of Cardiology Scientific Sessions. Atlanta, GA, USA, 14-16 March 2010.
26. Leon MB, Mauri L, Popma JJ et al. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the Taxus paclitaxel-eluting stent in de novo native coronary lesions 12 month outcomes from the ENDEAVOR IV trial. J. Am. Coll. Cardiol. 55(6), 543-554 (2010).
27. Camenzind E, Wijns W, Mauri L et al. Rationale and Design of the Patient Related Outcomes with Endeavor Versus Cypher Stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am. Heart J. 158(6), 902-909 e905 (2009).
28. Meredith IT, Worthley S, Whitbourn R et al. The next-generation Endeavor Resolute stent: 4 month clinical and angiographic results from the Endeavor Resolute first-in-man trial. EuroIntervention 3(1), 50-53 (2007).
29. Udipi K, Melder RJ, Chen M et al. The next generation endeavor resolute stent: role of the Bio-Linx Polymer System. EuroIntervention 3(1), 137-139 (2007).
30. Meredith IT, Worthley S, Whitbourn R et al. Clinical and angiographic results with the next-generation resolute stent system: a prospective, multicenter, first-in-human trial. JACC 2(10), 977-985 (2009).
31. Nikolsky E. Endeavor Resolute: clinical results to 36 months. Presented at: TCT Conference 2009. San Francisco, CA, USA, 21-25 September 2009.
32. Serruys PW, Silber S, Garg S et al. Comparison of zotarolimus-eluting and everolimus-eluting coronary stents. N. Engl. J. Med. 363(2), 136-146 (2010).
33. Costa Jr JR , Abizaid A, Feres F et al. EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. EuroIntervention 4(1), 53-58 (2008).
34. Abizaid A. Single center, first in man study of the Elixir Novolimus eluting coronary stent system with durable polymer: 24 month clinical safety and efficacy results. Am. J. Cardiol. 104, 158D (2009).
35. Serruys PW, Garg S, Abizaid A et al. A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9 month follow-up results of the EXCELLA II study. EuroIntervention 6(2), 195-205 (2010).
36. Rutsch W. Multi-center first-in-man study with the lowest known limus dose on the Elixir Medical myolimus eluting coronary stent system with a durable polymer: nine month clinical and six month angiographic and IVUS follow-up. Presented at: EuroPCR. Barcelona, Spain, 19-22 May 2009.
37. Schofer J. Multicenter, first-in-man study of the Elixir Myolimus coronary stent system with bioabsorbable polymer: 12 month clinical and angiographic/IVUS results. Presented at: EuroPCR. Paris, France, 25-28 May 2010.
38. Kastrati A, Mehilli J, Dirschinger J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 103(23), 2816-2821 (2001). (Pubitemid 32550070)
39. Pache J, Kastrati A, Mehilli J et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J. Am. Coll. Cardiol. 41(8), 1283-1288 (2003). (Pubitemid 36438988)
40. Kereiakes DJ, Cannon LA, Feldman RL et al. Clinical and angiographic outcomes after treatment of de novo coronary stenoses with a novel platinum chromium thin-strut stent: primary results of the PERSEUS (Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the Taxus Element Paclitaxel-Eluting Coronary Stent System) trial. J. Am. Coll. Cardiol. 56(4), 264-271 (2010).
41. Kereiakes DJ. Taxus PERSEUS: a novel platinum chromium, thin-strut Taxus Element stent for the treatment of de novo coronary stenoses. Presented at: i2 summit. American College of Cardiology. Atlanta, USA, 15 March 2010.
42. Peled A, Kollet O, Ponomaryov T et al. The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. Blood 95(11), 3289-3296 (2000). (Pubitemid 30428455)
43. Blindt R, Vogt F, Astafieva I et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol. 47(9), 1786-1795 (2006).
44. Stefanadis C, Toutouzas K, Stefanadi E, Kolodgie F, Virmani R, Kipshidze N. First experimental application of bevacizumab-eluting PC coated stent for inhibition of vasa vasorum of atherosclerotic plaque: angiographic results in a rabbit atheromatic model. Hellenic. J. Cardiol. 47(1), 7-10 (2006).
45. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105(15), 1756-1759 (2002). (Pubitemid 34408880)
46. Pendyala L, Yin X, Li J et al. Polymer-free cerivastatin-eluting stent shows superior neointimal inhibition with preserved vasomotor function compared to polymer-based paclitaxel-eluting stent in rabbit iliac arteries. EuroIntervention 6(1), 126-133 (2010).
47. Basalus MW, Ankone MJ, van Houwelingen GK, de Man FH, von Birgelen C. Coating irregularities of durable polymer-based drug-eluting stents as assessed by scanning electron microscopy. EuroIntervention 5(1), 157-165 (2009).
48. Otsuka Y, Chronos NA, Apkarian RP, Robinson KA. Scanning electron microscopic analysis of defects in polymer coatings of three commercially available stents: comparison of BiodivYsio, Taxus and Cypher stents. J. Invasive Cardiol. 19(2), 71-76 (2007).
49. Windecker S, Serruys PW, Wandel S et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 372(9644), 1163-1173 (2008).
50. Serruys PW. BIOMATRIX: first report from the 3 year LEADERS trial. Presented at: Transcatheter Cardio-vascular Therapeutics 2010. Washington DC, USA, 21-25 September 2010.
51. Garg S, Serruys PW. Coronary stents: looking forward. J. Am. Coll. Cardiol. 56(Suppl. 10), S43-S78 (2010).
52. Hamilos MI, Ostojic M, Beleslin B et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion. J. Am. Coll. Cardiol. 51(22), 2123-2129 (2008). (Pubitemid 351721001)
53. Chevalier B, Silber S, Park SJ et al. Randomized comparison of the NOBORI biolimus A9-eluting coronary stent with the Taxus libertè paclitaxel-eluting coronary stent in patients with stenosis in native coronary artery. Circ. Cardiovasc. Inter. 2, 188-195 (2009).
54. Wessely R. New drug-eluting stent concepatients. Nat. Rev. Cardiol. 7(4), 194-203 (2010).
55. Ormiston JA, Abizaid A, Spertus J et al. Six month results of the NEVO RES-ELUTION I (NEVO RES-I) trial: a randomized, multicenter comparison of the nevo sirolimus-eluting coronary stent with the Taxus liberte paclitaxel-eluting stent in de novo native coronary artery lesions. Circ. Cardiovasc. Interv. 3(6), 556-564 (2010).
56. Abizaid A. The NEVO RES Elution I study: a randomized multicenter comparison of the NEVO reservoir-based Sirolimus eluting-stent with the Taxus Libertè Paclitaxel-eluting stent: first presentation of the 12 month outcomes. Presented at: EuroPCR. Paris, France, 25-28 May 2010.
57. Han Y, Jing Q, Xu B et al. Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in 'real-world' practice: 18 month clinical and 9 month angiographic outcomes. JACC Cardiovasc. Interv. 2(4), 303-309 (2009).
58. Chamie D, Costa Jr JR , Abizaid A et al. Serial angiography and intravascular ultrasound: results of the SISC Registry (Stents In Small Coronaries). JACC Cardiovasc. Interv. 3(2), 191-202 (2010).
59. Botelho R. The Cardiomind Sparrow DES Program (CARE II): a bioabsorbable polymer sirolimus eluting 'micro-stent'. Presented at: TCT Conference 2009. San Francisco, CA, USA, 21-25 September 2009.
60. Byrne RA, Kufner S, Tiroch K et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. Heart 95(18), 1489-1494 (2009).
61. Adriaenssens T, Mehilli J, Wessely R et al. Does addition of estradiol improve the efficacy of a rapamycin-eluting stent? Results of the ISAR-PEACE randomized trial. J. Am. Coll. Cardiol. 49(12), 1265-1271 (2007). (Pubitemid 46476843)
62. Verheye S, Agostoni P, Dawkins KD et al. The GENESIS (Randomized, Multicenter Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel- Eluting Coronary Stent System in Patients with de novo Lesions of the Native Coronary Arteries) trial. JACC Cardiovasc. Interv. 2(3), 205-214 (2009).
63. Byrne RA, Mehilli J, Iijima R et al. A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs polymer-based drug-eluting stents. Eur. Heart J. 30(8), 923-931 (2009).
64. Byrne RA, Kastrati A, Tiroch K et al. 2 year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based cypher and endeavor, drug-eluting stents. J. Am. Coll. Cardiol. 55, 2536-2543 (2010).
65. Lee CW. CiloTaxTM Dual-drug eluting stent a prospective, randomized, controlled trial of a stent eluting cilostazol and paclitaxel. Presented at: TCT Conference 2009. San Francisco, CA, USA, 21-25 September 2009.
66. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-967 (1997). (Pubitemid 27087709)
67. De Winter R, e-HEALING Registry. Can a pro-healing stent make a difference? final 12 month outcomes from the e-HEALING 5,000 patient registry using the EPC-Coated genous stent. Presented at: TCT Conference 2009. San Francisco, CA, USA, 21-25 September 2009.
68. Beijk MA, Klomp M, Verouden NJ et al. Genous™ endothelial progenitor cell capturing stent vs the Taxus Liberte stent in patients with de novo coronary lesions with a high-risk of coronary reste-nosis: a randomized, single-centre, pilot study. Eur. Heart J. 31(9), 1055-1064 (2009).
69. Granada JF, Inami S, Aboodi MS et al. Development of a novel prohealing stent designed to deliver sirolimus from a biodegradable abluminal matrix. Circ. Cardiovasc. Interv. 3(3), 257-266 (2010).
70. Granada JF. The Orbus-neich EPC-coated bioabsorbable polymer sirolimus-eluting stent program. Presented at: Transcatheter Cardiovascular Therapeutics. San Francisco, CA, USA, 21 September 2010.
71. Tada N, Virmani R, Grant G et al. Polymer-free biolimus a9-coated stent demonstrates more sus-tained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model. Circ. Cardiovasc. Interv. 3(2), 174-183 (2010).
72. Virmani R. Are polymer-free DES safer? Observations from experimental studies in animal models. Presented at: Transcatheter Therapeutics 2009. San Francisco, CA, USA, 21-25 September 2009.
73. Grube E. BioFreedom first in man progress report. A prospective, randomized, non-inferiority trial comparing biolimus drug coated-polymer free stent 'BioFreedom™' versus paclitaxel-eluting stent with durable polymer 'Taxus™ Liberté™'. 4 month cohort follow-up. Presented at: TCT Conference 2009. San Francisco, USA, 21-25 September 2009.
74. Costa Jr JR , Abizaid A, Costa R et al. 1 year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC Cardiovasc. Interv. 2(5), 422-427 (2009).
75. Tanguay JF, Zidar JP, Phillips HR III, Stack RS. Current status of biodegradable stents. Cardiol. Clin. 12(4), 699-713 (1994). (Pubitemid 24375058)
76. Ormiston JA, Serruys PW, Regar E et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 371(9616), 899-907 (2008). (Pubitemid 351384734)
77. Serruys PW, Ormiston JA, Onuma Y et al. A bioabsorbable everolimus-eluting coronary stent sys-tem (ABSORB): 2 year outcomes and results from multiple imaging methods. Lancet 373(9667), 897-910 (2009).
78. Onuma Y. Three year results of clinical follow-up after a bioresorbable everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 6(4), 447-453 (2010).
79. Post MJ, de Graaf-Bos AN, van Zanten HG, de Groot PG, Sixma JJ, Borst C. Thrombogenicity of the human arterial wall after interventional thermal injury. J. Vasc. Res. 33(2), 156-163 (1996). (Pubitemid 26089633)
80. Yamawaki T, Shimokawa H, Kozai T et al. Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. J. Am. Coll. Cardiol. 32(3), 780-786 (1998). (Pubitemid 28435269)
81. Ormiston J, Serruys PW. Bioabsorbable coronary stent. Cardiovasc. Inter. 1(2), 255-260 (2009).
82. Jabara R. Polyanhydride based on salicylic acid and adipic acid anhydride. Presented at: EuroPCR. Barcelona, Spain, 19-22 May 2009.
83. Meredith IT, Ormiston J, Whitbourn R et al. First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial. EuroIntervention 1(2), 157-164 (2005).
84. Meredith IT, Ormiston J, Whitbourn R, Kay IP, Muller D, Cutlip DE. Five year clinical follow-up after implantation of the Endeavor zotarolimus-eluting stent: ENDEAVOR I, first-in-human study. Catheter Cardiovasc. Interv. 74(7), 989-995 (2009).
85. Fajadet J, Wijns W, Laarman GJ et al. Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine- encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 114(8), 798-806 (2006). (Pubitemid 44268230)
86. Van Leeuwen F. Randomised trial comparing the ENDEAVOR zotarolimus-eluting stent and the driver bare metal stent in single de novo native coronary artery lesions: five year clinical follow-up of ENDEAVOR II. Presented at: EuroPCR. Barcelona, Spain, 19-22 May 2009.
87. Kandzari DE, Leon MB, Popma JJ et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J. Am. Coll. Cardiol. 48(12), 2440-2447 (2006). (Pubitemid 44881222)
88. Eisenstein EL, Leon MB, Kandzari DE et al. Long-term clinical and economic analysis of the En-deavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3 year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in de novo Native Coronary Artery Lesions). JACC Cardiovasc. Interv. 2(12), 1199-1207 (2009).
89. Leon MB. First Presentation of the ENDEAVOR IV 3 year results. Presented at: TCT Conference 2009. San Francisco, CA, USA, 21-25 September 2009.
90. Park DW, Kim YH, Yun SC et al. Comparison of zotarolimus-eluting stents with sirolimus- and pa-clitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J. Am. Coll. Cardiol. 56(15), 1187-1195 (2010).
91. Lotan C, Meredith IT, Mauri L, Liu M, Rothman MT. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12 month data from the E-Five registry. JACC Cardiovasc. Interv. 2(12), 1227-1235 (2009).
92. Meredith IT. Real world outcomes in patients with coronary artery disease treated with the endeavor ZES: 2 year results from the E-Five registry. Presented at: EuroPCR. Barcelona, Spain, 19-22 May 2009.
93. Wiemer M, Serruys PW, Miquel-Hebert K et al. Five year long-term clinical follow-up of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT FIRST trial. Catheter. Cardiovasc. Interv. 75(7), 997-1003 (2010).
94. Garg S, Serruys PW, Miquel-Hebert K. Four year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial. Catheter. Cardiovasc. Interv. DOI: 10.1002/ ccd.22770 (2010) (Epub ahead of print).
95. Stone G. The XIENCE V-PROMUS everolimus-eluting stent: comprehensive update of the clinical trial program. Presented at: Transcatheter Cardiovascular Therapeutics. San Francisco, CA, USA, 21 September 2009.
96. Stone G. SPIRIT IV: two year results from a prospective randomized trial of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 21-25 September 2010.
97. Chevalier B. SPIRIT V single arm study: 2 year follow-up. Presented at: EuroPCR. Paris, France, 25-28 May 2010.
98. Smits P. COMPARE: two year results from a prospective randomized trial of everolimus-eluting stents compared to paclitaxel-eluting stents in patients with coronary artery disease. Presented at Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 21 September 2010.
99. Jensen L. SORT OUT 4: a prospective randomized trial of everolimus-eluting stents and sirolimus-eluting stents in patients with coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 21 September 2010.
100. Byrne R. ISAR-TEST-4: two year clinical and angiographic outcomes from a prospective randomized trial of everolimus-eluting stents and sirolimus-eluting stents in patients with coronary artery disease. Presented at: Transcatheter Cardiovascular Therapeutics. Washington, DC, USA, 21 September 2010.
101. Serruys P. RESOLUTE All-Comers trial: a randomized comparison of a zotarolimus-eluting stent with an everolimus-eluting stent for percutaneous coronary intervention. Primary results. Presented at: EuroPCR. Paris, France, 25-28 May 2010.
102. Dawkins K. The Element stent technology. Presented at: EuroPCR. Paris, France, 25-28 May 2010.
103. Grube E, Schofer J, Hauptmann KE et al. A novel paclitaxel-eluting stent with an ultrathin abluminal biodegradable polymer 9 month outcomes with the JACTAX HD stent. JACC Cardiovasc. Interv. 3(4), 431-438 (2009).
104. Dani S, Kukreja N, Parikh P et al. Biodegradable-polymer-based, sirolimus-eluting supralimus stent: 6 month angiographic and 30 month clinical follow-up results from the series I prospective study. EuroIntervention 4(1), 59-63 (2008).
105. Vranckx P, Serruys PW, Gambhir S et al. Biodegradable-polymer-based, paclitaxel-eluting Infinnium stent: 9 month clinical and angiographic follow-up results from the SIMPLE II prospective multi-centre registry study. EuroIntervention 2(3), 310-317 (2006).
106. Onuma Y, Serruys P, den Heijer P et al. MAHOROBA, first-in-man study: 6 month results of a bio-degradable polymer sustained release tacrolimus-eluting stent in de novo coronary stenoses. Eur. Heart J. 30(12), 1477-1485 (2009).
107. Mehilli J, Kastrati A, Wessely R et al. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 113(2), 273-279 (2006).
108. Garg S, Serruys PW. Coronary stents: current status. J. Am. Coll. Cardiol. 56(10 Suppl.), S1-42 (2010).
109. Spertus J. NEVO RES-Elution I QOL. Oral presentation. Presented at: TCT Conference 2009. San Francisco, CA, USA, 24 September 2009.
110. Schülen H. The ISAR Polymer-free Single and Dual Drug-eluting stent Programs. Oral presentation. Presented at: TCT Conference 2009. San Francisco, CA, USA, 22 September 2009.
111. Serruys PW. Futuristic...Bioabsorbable Drug-eluting Stents. Oral presentation. Presented at: TCT Conference 2009. San Francisco, CA, USA, 24 September 2009.